As support times for left ventricular assist devices (LVADs) become longer, several complications requiring device exchange may occur. To our knowledge, this is the first Canadian report regarding implantable LVAD exchange.
L
eft ventricular assist devices (LVAD) have become an important tool to manage refractory heart failure. In North America, the numbers of implants have substantially increased over the past decade. [1] [2] [3] With their approval for use as destination therapy (DT) and the improvement in mechanical durability of the newer devices, average support times have surpassed 12 months, 1, 3, 4 and device exchange owing to complications will inevitably be required for a variety of indications. 5, 6 Although uncommon, device malfunction requiring replacement is a serious and potentially fatal complication. 2, 5 Several risk factors have been identified, such as the use of first-generation devices, obesity, older age and renal failure. 1, 7 To our knowledge, no Canadian centre has reported on their experience with these cases, thus far. Therefore, we present our experience with device malfunction leading to exchange in a consecutive series of implantable, continuous flow LVAD recipients.
Methods
This study was reviewed and approved by the research ethics board of Toronto General Hospital, Toronto, Canada. We reviewed the clinical records of consecutive patients who underwent LVAD implantation at our institution between June 2006 and October 2015 to identify those who had required device exchange. We collected detailed information on these selected individuals, including demographic characteristics, initial device implanted, time to device failure, replacement devices, total support time and outcomes. Cases of temporary paracorporeal LVADs were not included.
Results
From June 2006 to October 2015, 122 consecutive patients underwent LVAD implantation at our instution. We identified 8 patients who required a total of 9 LVAD exchanges (1 patient required 2 device exchanges). Demographic characteristics of the patients are shown in Table 1 . Two patients were women, and the overall mean age was 54 years (range 39-66 years). Mean body mass index (BMI) and body surface area (BSA) were 25 (range 21.2-29.4), and 1.91 m 2 (range 1.65-2.23 m 2 ), respectively. All patients had a previous automatic implantable cardiac defibrillator (AICD) implants, and 3 patients had prior coronary artery bypass surgery. With respect to the etiology of their heart failure syndrome, 4 patients had ischemic cardiomyopathy, 3 had dilated cardiomyopathy and 1 had hypertrophic cardiomyopathy. Table 2 lists the initial device, time to device failure, replacement device, total support time and outcomes for all 8 patients. Excluding the 2 cases of immediate device replacement, the mean time of support to exchange was 225 days, and mean time from exchange to any outcome was 245 days. Three patients were successfully bridged to transplant, and at the time of data collection 2 were currently supported awaiting transplant. Three patients in this series died due to multisystem organ failure (day 17), sepsis (day 673) or recurrent gastrointestinal bleeding (day 432), after device replacement.
The first patient in our series presented emergently with a driveline fracture (Fig. 1) and underwent successful exchange as a bridge to heart/lung transplant, which was performed 5 months later. Two additional patients displayed early device malfunction on the day of implant, necessitating device exchange. Both presented with poor pump flow in the immediate perioperative period. The HeartWare HVAD device displayed abnormal waveforms that failed to normalize with time; therefore, mechanical entrainment of particulate matter within the pump housing was suspected. An initial DuraHeart device was explanted owing to poor flow and a suspected inflow cannula obstruction. The device was exchanged successfully for a HeartMate II (HMII) device. Interestingly, this same patient presented 225 days later with decompensated heart failure and suspected pump thrombus ( Fig. 2 ) of his HMII and underwent successful subcostal device exchange.
Four patients presented with biochemical and hematological evidence of hemolysis and pump thrombosis; 3 were subacute presentations admitted from the clinic for investigation and 1 presented to the emergency department with decompensated heart failure. They underwent ramp echocardiography studies, with 2 showing results compatible with pump obstruction, such as left ventricular dilation despite increasing pump speeds. The other 2 exams were inconclusive. All 4 patients underwent successful pump exchange. One patient presented with peripheral embolism, right ventricular infarct and biochemical evidence of hemolysis 1 week after implant, requiring exchange of the device. He was successfully transplanted 2 months later. Table 3 outlines the parameters on the pumps at the time of exchange. There was great variability in the data, and device interrogation did not always reveal pump malfunction. A high index of suspicion, abnormal biochemistry and an echocardiogram demonstrating inadequate pump performance (e.g., poor LV decompression, persistent aortic valve opening) led to the diagnosis of pump thrombus. Indirect factors, such as patient frailty, prognosis and life expectancy, were discussed on a case-bycase basis to facilitate the decision-making process.
The average international normalized ratio (INR), percentage of time below target INR, platelet count, creatinine and peak lactate dehydrogenase (LDH) level between the first implant and exchange are described in Table 4 . Of the 6 patients who had confirmed pump thrombosis, 2 patients had an average INR below 2. The remaining 4 patients demonstrated an average INR slightly above 2 (range 2-2.25). As per protocol, all patients received antiplatelet therapy as well. Platelet counts in the cases of thrombosis were below 200 000/mm 3 , except in 1 case. Notably high levels of LDH were detected in all of our cases of late pump thrombosis.
Throughout our program's experience, there were 2 patients with established diagnosis of pump thrombosis not treated with LVAD exchange. The first patient presented after 2 years of HVAD support as a bridge to candidacy with hematuria, LVAD alarms indicative of device thrombosis and elevated LDH. She was treated with thrombolytic therapy, with dramatic improvement of pump flows (Fig. 3) . Notably, the patient was on suppressive antibiotic therapy for chronic driveline infection. Early during recovery, ischemic colitis and lower gastrointestinal bleed developed, requiring a laparotomy. Afterwards, she demonstrated favourable progress and currently remains supported by her device.
The second patient had an HMII implanted as DT. After 2 years of support, he presented with recurrent transient ischemic attacks, LDH elevation and hematuria. He was on warfarin and acetylsalicylic acid (ASA) therapy, had an INR above 2 and was extensively investigated with repeated echocardiography, laboratory and clinical assessments. Owing to the reassuring nature of the clinical scenario, the team opted for conservative treatment, increasing his target INR and adding clopidogrel to his antiplatelet regimen. He continues to be closely followed in clinic and has not presented with worsening symptoms 4 years after initial implant. Of the 6 "late" exchanges in our series, 4 were successfully performed using a subcostal approach, avoiding resternotomy. The reasons for resternotomy were suspicion of device infection in 1 patient (case 4) and the need for concomitant right ventricular assist device implantation in another patient (case 6). This patient presented to us with right ventricular infarct and peripheral embolization. There were no significant differences in cardiopulmonary bypass time (46 ± 27.2 min v. 36.5 ± 13.9 min), length of stay in the intensive care unit (ICU; (Table 5) . The overall mortality of our series was 33% (n = 3). Although apparently high, this may simply reflect the limited number of cases thus far. Notably, death within 30 days of pump exchange occurred in only 1 patient (case 2).
discussion
To our knowledge, we have described the first Canadian single-centre experience with LVAD exchange. Device complication requiring exchange occurs at a relatively low frequency; our series has shown that 7.3% of patients required LVAD replacement, and this is compatible with the overall results from larger studies, such as the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). 1, 6, 8, 9 However, the incidence of device complications requiring replacement appears to be rising, especially due to pump thrombosis. Kirklin and colleagues, 2 in the HMII thrombosis substudy of the INTERMACS registry, have shown that there has been an increase in pump exchange due to thrombosis at 6 months starting in 2012. Starling and colleagues 10 also found an increase in the incidence in pump thrombosis, especially in patients who underwent their first implantation more recently. Presumably, the realization of elevated LDH as a marker of pump thrombosis before pump malfunction has led to the higher detection rates. 11 Our study corroborates the existing literature by showing that the main etiology for device exchange in continuous flow pumps is thrombosis. Six of our 9 exchanges were performed for suspected and subsequently confirmed pump thrombosis. Although previous publications have demonstrated that approximately 50% of replacements are secondary to this complication, 2,3,5,6,8,10,12 our higher incidence may simply be a reflection of our limited number of cases thus far. The reason for this increase in pump thrombosis in recent years is unclear. The major risk is most probably an inadequate anticoagulation strategy. A consensus target INR has not been determined for the LVAD population. 2 Slaughter and colleagues 13 have shown that patients transitioned directly to warfarin and ASA therapy post-LVAD implant without heparin bridging had no increase in short-term thrombotic events. Additionally, Boyle and colleagues 14 also demonstrated the long-term safety of maintaining this population's INR between 1.5 and 2.5 in addition to ASA therapy. These 2 papers were published in 2010 and 2009, respectively. Interestingly, the peak incidence of pump thrombosis occurred in 2012, likely reflecting the delayed effect of a reduced anticoagulation strategy.
Our institution's protocol includes oral anticoagulation therapy for all patients undergoing LVAD implantation, including an initial bridging period with heparin until adequate INR levels have been reached. Shortly after the report by Slaughter and colleagues, 13 we also dispensed with heparin bridging owing to observed cases of late pericardial effusions. However, with the recent reports of pump thrombus in the HMII population, we have once again reinstituted heparin bridging starting on the first postoperative day. We reviewed the coagulation studies from our set of patients and found that we also had trouble maintaining therapeutic anticoagulation, despite a constant target INR of 2-2.5. All patients showed a very unstable INR, with results varying around 2 (above and below). This once again corroborates with the hypothesis that we may need to be more aggressive when controlling anticoagulation in this population. 2 The diagnosis of pump thrombosis is not always straightforward. The typical presentation includes increased pump power, hemolysis or recurrent decompensated heart failure. Among others, LDH levels appear to be a good indicator of thrombosis, as seen in all our cases of late thrombosis. However, in the case of early thrombosis, the increase of LDH (case 6) was not significant. In this case, the patient presented with recurrent heart failure, and hemodynamic instability gradually developed. Despite having LDH levels within postoperative norms, there was a high suspicion for pump thrombosis, and thrombus was in fact detected in the outflow cannula during the second operation. Echocardiography cannot evaluate the pump directly; however, it may be beneficial to detect indirect evidence of thrombosis, such as left ventricular dilatation, consistent opening of the aortic valve during systole despite high pump speeds and a shift of the interventricular septum to the right. 15 As noted previously, we routinely performed echocardiography and ramp studies in our subacute presenting patients with suspected thrombosis.
The role of computed tomography in this case is to allow the evaluation of areas not well visualized by the echocardiography, such as outflow cannula position and extracardiac features. However, this modality has the disadvantage of not being able to evaluate flow. Accordingly, this modality has proven its usefulness in cases requiring more accurate visualization, as in suspected left ventricular thrombus formation and device infection. 16 Canadian health care, as a government-funded service, invariably presents funding limitations. This limits the number of devices we are able to implant, and we are required to carefully select the patients who would derive the most benefit from the intervention. Although medical therapy with intensified anticoagulation (including the use of thrombolytics) has been reported, we and others continue to believe that device exchange is the preferred management strategy for suspected and/or proven pump thrombus. 11 As mentioned above, indirect factors, such as patient frailty and overall prognosis, should also be discussed in each case and considered when making therapeutic decisions.
In regard to the incidence of pump thrombosis across the different LVAD models, the present series demonstrated 6 cases of thrombosis out of 82 implanted HMII devices (7.3%) and 1 case out of 31 implanted HVAD devices (3.2%). Of the 4 DuraHeart devices implanted during the study period, 1 required exchange owing to obstruction of the inflow cannula. Despite the limited number of cases, there does not appear to be a difference in thrombosis rates among these devices. This is in accordance with the current literature on continuous flow LVADs. We have used the subcostal approach for exchanging an HMII when feasible. We do not reverse anticoagulation with fresh frozen plasma or vitamin K for this approach. It may be advantageous to keep the INR in the therapeutic range right after device exchange for patients with pump thrombosis. Ota and colleagues 9 described several benefits of a subcostal approach for exchanging an HMII, including less postoperative bleeding, less blood transfusion requirement, decreased time to extubation and decreased overall length of stay in the ICU. In our experience, time on cardiopulmonary bypass, length of stay in the ICU and hospital stay were comparatively shorter with the subcostal approach than with resternotomy. However, the small number of cases precluded this finding from achieving statistical significance. Further experience may corroborate a statistically significant advantage of the subcostal approach.
Limitations
Our study has some clear limitations, starting with the number of cases we presented. We are not able at this point to proceed with an adequate statistical analysis of our findings. Further studies are needed, possibly combining data from other Canadian LVAD programs, allowing for adequate comparisons with our population of patients who did not require device replacement and exploring the long-term outcomes of these individuals. We would like to emphasize that, at this point, meaningful conclusions are difficult to make and apply to other programs. However, given the ethical considerations of pump exchange in jurisdictions where funding is limited or even absent, as in the Canadian setting, we believe our results to be clinically important and, as we have described, at least comparable to the large North American registries. Even with this relatively small series, and in accordance with previous literature, device exchange is a safe and effective method of managing suspected pump thrombus, being the preferred treatment option in our program.
conclusion
To our knowledge, this is the first described Canadian experience with LVAD exchange. We confirm that pump thrombosis is by far the most important cause for device exchange in the new-generation devices, raising the issue of whether our current anticoagulation strategy is adequate. Also, despite the high-risk population, device exchange can be performed with acceptable morbidity and mortality. A less invasive subcostal approach has proven to be safe with reproducible results.
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